Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Closed for comments This consultation ended on at Request commenting lead permission
1 Recommendations
1.1 Rucaparib is not recommended, within its marketing authorisation, for maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults.
1.2 This recommendation is not intended to affect treatment with rucaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Why the committee made these recommendations
The clinical evidence shows that rucaparib extends the time until cancer progresses compared with routine care. How much longer people live after taking rucaparib is uncertain because the data from the trial are not available yet. However, the cost-effectiveness estimates are higher than what NICE normally considers acceptable, so it is not recommended for routine use in the NHS.
Rucaparib does not have the plausible potential to be cost effective so it does not meet NICE's Cancer Drugs Fund criteria. Therefore, it is not recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation